Accedi

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.

A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote glycine release, increasing chloride influx into postsynaptic neurons and reducing excitability.

GABA mimetics, such as baclofen, activate GABAB receptors, leading to hyperpolarization of neuronal membranes and reduced excitability. Baclofen suppresses the release of excitatory transmitters in the brain and spinal cord, suppressing sensory afferents, interneurons, and motor neurons.

Benzodiazepines like diazepam bind to the allosteric site of GABAA receptors and facilitate GABA's action in the CNS. Diazepam reduces spasticity, particularly in the spinal cord, but sedation can occur at doses required to reduce muscle tone.

Tags
Spasmolytic AgentsMuscle SpasmsSpasticityChemical ClassificationCentrally Acting Spasmolytics2 agonistTizanidine2 adrenoceptorsGlutamateGlycineChloride InfluxGABA MimeticsBaclofenGABAB ReceptorsHyperpolarizationBenzodiazepinesDiazepamGABAA ReceptorsCNS Sedation

Dal capitolo 7:

article

Now Playing

7.11 : Spasmolytic Agents: Chemical Classification

Skeletal Muscle Relaxants

824 Visualizzazioni

article

7.1 : Giunzione Neuromuscolare E Blocco

Skeletal Muscle Relaxants

2.6K Visualizzazioni

article

7.2 : Classificazione dei miorilassanti scheletrici

Skeletal Muscle Relaxants

2.3K Visualizzazioni

article

7.3 : Bloccanti neuromuscolari non depolarizzanti (competitivi): meccanismo d'azione

Skeletal Muscle Relaxants

1.2K Visualizzazioni

article

7.4 : Bloccanti neuromuscolari non depolarizzanti (competitivi): azioni farmacologiche

Skeletal Muscle Relaxants

342 Visualizzazioni

article

7.5 : Bloccanti neuromuscolari non depolarizzanti (competitivi): farmacocinetica

Skeletal Muscle Relaxants

403 Visualizzazioni

article

7.6 : Bloccanti depolarizzanti: meccanismo d'azione

Skeletal Muscle Relaxants

992 Visualizzazioni

article

7.7 : Bloccanti depolarizzanti: Farmacocinetica

Skeletal Muscle Relaxants

275 Visualizzazioni

article

7.8 : Miorilassanti ad azione diretta: Dantrolene e Tossina botulinica

Skeletal Muscle Relaxants

596 Visualizzazioni

article

7.9 : Miorilassanti scheletrici: effetti avversi

Skeletal Muscle Relaxants

302 Visualizzazioni

article

7.10 : Miorilassanti scheletrici: usi terapeutici

Skeletal Muscle Relaxants

430 Visualizzazioni

article

7.12 : Miorilassanti ad azione periferica e centrale: un confronto

Skeletal Muscle Relaxants

2.9K Visualizzazioni

article

7.13 : Miorilassanti ad azione centrale: usi terapeutici

Skeletal Muscle Relaxants

546 Visualizzazioni

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati